Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
Phase 2 N=38 Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Average Lissamine Green Staining in the Study Eye — -0.65 score on a scale
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
N/A N=161 Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Impact of Dry Eye on Everyday Life - Symptom Bother (IDEEL-SB) Questionnaire Score at Day 30 — -16.95 score on a scale — p=<.0001
Phase 3 N=242 A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
Dry Eye Syndromes
Primary: Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score — 41.12; 39.63; -15.61; -13.16 score on a scale
N/A N=781 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Ocular Surface Disease Index (OSDI) Total Score at Baseline — 40.3 Scores on a Scale
Phase 2 N=150 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Schirmer's — 1.3; 2.1; 0.9 mm
N/A N=235 TearCare System to Treat Dry Eye Disease
Dry Eye · Meibomian Gland Dysfunction
Primary: Change in Tear Break-Up Time (TBUT) From Baseline — 3.02; 2.58 Seconds
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
Phase 3 N=80 A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Least Squares Mean Percentage Change From Baseline in Goblet Cell Density at Day 90 for 0.003% AR-15512 — 94.61 percent change — p=0.1765
Phase 3 N=315 Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
Dry Eye Syndromes
Primary: Change From Baseline in Ocular Surface Disease Index© Questionnaire Score — 41.48; 38.27; 40.28; 40.18 Score on a scale
Phase 2 N=138 Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Number of Subjects With Adverse Events — 13; 15; 10 Participants
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
Phase 3 N=40 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
Dry Eye Syndrome
Primary: Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score — -6.8 score on a scale
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
Phase 2 N=201 Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (tCFS) at Day 60 — -2.04; -1.65; -2.15; -1.54 tCFS score on a scale of 0 - 20
Phase 4 N=51 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
Dry Eye Syndromes
Primary: Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye — 7.05; -1.51 score on a scale
Phase 2 N=183 Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test — 3.02; 2.15; 2.35; 1.35 mm
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
Phase 3 N=236 Trial of CF101 to Treat Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24 — 15; 13; 21; 61 participants
Phase 3 N=757 A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease — 0; 0 Participants
Phase 2 N=158 A Clinical Trial to Assess Subjects With Dry Eye Disease.
Dry Eye
Primary: Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber — 0.066; 0.183 units on a scale
N/A N=15 Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
Aqueous Deficient Dry Eye · Meibomium Gland Dysfunction
Primary: Visual Quality — 0.3; 0.32; 0.19; 0.3 microns
N/A N=29 Study of the TearCare System in Dry Eye Disease
Dry Eye
Primary: Mean Change in Tear Break-Up Time (TBUT) at 1-month From Baseline — 3.1 seconds
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
Phase 2 N=102 A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Dry Eye
Primary: Inferior Corneal Staining Score — -0.08; -0.03 units on a scale
Phase 2 N=305 Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — -25.66; -25.14; -29.95; -24.81 units on a scale
Phase 2 N=300 A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Syndrome
Primary: Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness. — -0.7; -0.5; -0.4 units on a scale
N/A N=286 Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis
Dry Eye Syndromes · Rheumatoid Arthritis
Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants